News
Press Release
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
REDWOOD CITY, CA – November 4, 2019 – Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced an agreement with…
Read morePublication / Presentation
Press Release
Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
REDWOOD CITY, CA – October 22, 2019 – Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced that preclinical in…
Read morePublication / Presentation
Press Release
Revolution Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
REDWOOD CITY, CA – September 17, 2019 – REVOLUTION Medicines, Inc., a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced dosing of the…
Read morePublication / Presentation
Publication / Presentation
News
Revolution Medicines snags $100M to attack RAS-mutated cancers
Revolution Medicines raised $100 million in series C financing to advance a stable of drugs aiming at what it calls “frontier targets” in cancer. These include a program targeting KRAS mutations, which were previously considered undruggable.…
Read more